MICC:NYSEThe Magnum Ice Cream Company N.V. Analysis
Data as of 2026-04-17 - not real-time
$14.15
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Technical indicators suggest a mixed picture. The price is trading below its 20‑day and 50‑day moving averages, the RSI sits in oversold territory and the MACD histogram has just turned positive, hinting at a possible short‑term bounce. However, volume is on a decreasing trend and the broader trend remains bearish, with the stock hovering just above a key support level.
Fundamentally, the spin‑off status provides a clear strategic focus but the valuation appears stretched. A DCF fair‑value estimate is far below the current market price, while the price‑to‑earnings and price‑to‑book multiples are markedly high for a consumer‑defensive business. The company shows modest profitability, low leverage relative to its equity base, and solid cash flow generation, yet earnings growth has stalled and analysts have issued a neutral “hold” rating. Recent earnings disappointment and litigation concerns add short‑term headwinds, but the brand portfolio and potential margin expansion remain attractive over a longer horizon.
Fundamentally, the spin‑off status provides a clear strategic focus but the valuation appears stretched. A DCF fair‑value estimate is far below the current market price, while the price‑to‑earnings and price‑to‑book multiples are markedly high for a consumer‑defensive business. The company shows modest profitability, low leverage relative to its equity base, and solid cash flow generation, yet earnings growth has stalled and analysts have issued a neutral “hold” rating. Recent earnings disappointment and litigation concerns add short‑term headwinds, but the brand portfolio and potential margin expansion remain attractive over a longer horizon.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near technical support with bearish trend
- Oversold RSI suggesting limited downside
- Recent earnings miss and decreasing volume
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Potential margin expansion from focused spin‑off operations
- High valuation relative to fair‑value estimate
- Improving cash flow but modest earnings growth
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong brand portfolio in a defensive consumer segment
- Continued valuation premium versus fundamentals
- Exposure to global currency and regulatory environments
Key Metrics & Analysis
Financial Health
Revenue Growth-4.10%
Profit Margin3.70%
P/E Ratio24.8
ROE17.88%
ROA8.72%
Debt/Equity539.65
P/B Ratio12.0
Op. Cash Flow$483.0M
Free Cash Flow$365.6M
Technical Analysis
TrendBearish
RSI37.1
Support$13.96
Resistance$15.40
MA 20$14.55
MA 50$15.67
MA 200$15.87
MACDBullish
VolumeDecreasing
Fear & Greed Index89.39
Valuation
Fair Value$3.22
Target Price$17.80
Upside/Downside25.80%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.62
Volatility20.68%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.